Pharmaceutical Pricing in Europe

Published 28.11.2014

Abstract

How are medicine prices decided upon in European countries? Which challenges do policy makers face? Which role do reimbursement aspects play in the pricing process? Are there communalities and similarities between European countries? This chapter provides information on pharmaceutical pricing policies in 30 European countries, including all 28 European Union Member States. Key pricing policies at ex-factory price level as well as in the supply chain will be presented. Medicine price data will be provided as an illustrative snapshort.

Authors

Sabine Vogler, Jaana E Martikainen

Additional Information

Open Access: no.
Cite as: Vogler, S., & Martikainen, J. E. (2015). Pharmaceutical Pricing in Europe. In ZUD. Babar (Ed.). Pharmaceutical Prices in the 21st Century (Pp. 343–370). Springer. https://doi.org/10.1007/978-3-319-12169-7_19

Research publications
Medicines
reimbursements for prescription drug costs
Jaana Martikainen

More publications

10.1.2025Childhood Family Income and Medication Use in Youth
12.12.2024Clinically Significant Psychological Distress Is Associated With the Need for Kela’s Rehabilitation Services Supporting the Ability to Study in Higher Education Students
5.12.2024Prescribing Patterns Before the Initiation of Novel Antidiabetic Medicines in Public, Occupational, and Private Healthcare: A Register Study Reflecting the Guidelines of Care in Type 2 Diabetes
2.12.2024The effectiveness of social security in the diverse and changing life situations of adolescents
27.11.2024Between Universalism and the Market Model: How the Introduction of the Early Childhood Education Voucher Has Affected the Early Childhood Education System